Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Trading Up 16.4% – Here’s Why

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) traded up 16.4% during mid-day trading on Thursday . The stock traded as high as $13.37 and last traded at $13.10. Approximately 1,369,571 shares traded hands during trading, an increase of 4% from the average daily volume of 1,317,666 shares. The stock had previously closed at $11.25.

Analysts Set New Price Targets

BAYRY has been the subject of a number of research reports. UBS Group raised shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research note on Monday, March 16th. Zacks Research upgraded Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a report on Friday, May 8th. DZ Bank raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Finally, Jefferies Financial Group upgraded Bayer Aktiengesellschaft to a “hold” rating in a research note on Friday, May 29th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.

Bayer Aktiengesellschaft Trading Up 16.4%

The stock has a market cap of $51.48 billion, a PE ratio of -20.47, a PEG ratio of 3.51 and a beta of 0.59. The company has a quick ratio of 0.70, a current ratio of 1.05 and a debt-to-equity ratio of 1.06. The stock’s fifty day moving average price is $10.92 and its 200 day moving average price is $11.47.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its earnings results on Tuesday, May 12th. The company reported $0.79 EPS for the quarter, beating the consensus estimate of $0.64 by $0.15. The business had revenue of $15.73 billion for the quarter, compared to the consensus estimate of $15.77 billion. Bayer Aktiengesellschaft had a positive return on equity of 17.61% and a negative net margin of 4.75%.Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, sell-side analysts forecast that Bayer Aktiengesellschaft will post 1.25 EPS for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.